Clinical Investigations and Precision Therapeutics Research Program

Program Leaders: Shridar Ganesan, MD, PhD and Janice M. Mehnert, MD

Overall Goals:

The Overall Goals of the Clinical Investigations and Precision Therapeutics (CIPT) Program are to translate outstanding science into early phase trials, to develop new diagnostic, prevention, and therapeutic strategies and to promote bidirectional translation from bench to bedside and back. This bidirectional translation of basic science discoveries and reverse translation of clinical findings is facilitated by collaborations with the Cancer Metabolism and Growth (CMG), Genome Instability and Cancer Genetics (GICG), and Cancer Pharmacology (CP) Programs. Translation of population science is facilitated by collaboration with the Cancer Prevention and Control (CPC) Program.

Specific Aims:

  • Target cell death and survival pathways in cancer. 
  • Target DNA repair and cell cycle checkpoint abnormalities in cancer. 
  • Develop tumor vaccines and rational combination of immuno-oncology approaches. 
  • Investigate markers of response and resistance to cancer therapy. 

Collaborating Research Programs:

Useful Links:


image that says give now and support cancer research with link to giving page





Robert Wood Johnson Barnabas Health logo with link to Partners page





ScreenNJ logo with link to website






Big Ten Cancer Research Consortium





Rutgers Health